Joeseph Renzulli, MD

Panelists discuss how recent data from the EMBARK study indicates that in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk for biochemical recurrence (BCR), enzalutamide combined with gonadotropin-releasing hormone (GnRH) significantly improves metastasis-free survival compared with monotherapy options, with no new safety signals reported.

Panelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.

Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.

Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.